Vineti Valuation, Funding & Investors
Vineti is valued at $28M as of June 2017.
Last Vineti valuation
$28M
Series A · Jun 2017
Last Vineti funding round
$33M
Series C · Oct 2020
Cumulative funding Vineti raised
$115M
across 4 funding rounds
Key investors in Vineti
Threshold
Lifeforce Capital
Canaan Partners
Casdin Capital
S32
GE Ventures
About Vineti
Vineti is a San Francisco-headquartered provider of the Personalized Therapy Management platform for cell and gene therapy supply chains. Launched in 2016, its cloud-based software automates patient journeys for CAR-T treatments targeting leukemias and lymphomas. The platform tracks therapies from manufacturing sites in Boston to clinics in Houston, ensuring regulatory compliance for FDA approvals. Vineti serves pharmaceutical companies commercializing therapies like Kymriah from Novartis and Yescarta from Gilead across clinical trials and global distribution.
Founded
2016
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$28M (Jun 2017)
Vineti Valuation
Vineti is currently valued at $28M, based on its Series A in June 2017.
The $14M round was led by GE Ventures, with participation from Mayo Clinic Ventures, Lifeforce Capital and Threshold.
Vineti valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2017 | Series A | $28M |
Vineti Funding History
Vineti has raised a total of $115M across 4 funding rounds.
Vineti's first fundraising round was a $14M Series A in June 2017. The most recent completed round was a $33M Series C in October 2020.
Vineti funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Oct 2020 | Series C | Cardinal Health (lead); McKesson Ventures; Canaan Partners; Casdin Capital; Novartis; S32; Lifeforce Capital; Marc Benioff; Threshold | $33M | - | Vineti is a digital platform of record for personalized therapeutics, providing cloud-based software that integrates logistics, manufacturing, and clinical data to manage complex supply chains for cell and gene therapies, ensuring chain of identity and custody. Co-founded by GE and Mayo Clinic, it supports both clinical and commercial stages of high-value advanced therapies like CAR-T and allogeneic treatments, with global expansion into Europe and Asia-Pacific. The Series C financing began with a $35 million round announced in February 2020, led by Cardinal Health, with participation from Novartis Pharma AG, Kite (a Gilead company), Canaan Partners, Threshold Ventures, Section 32, LifeForce Capital, Casdin Capital, and Hive Ventures. This brought total funding over $82 million, following a $33.5 million Series B and $13.8 million Series A. Funds supported platform enhancement, new product development, and commercial growth, with Cardinal Health's Joe DePinto joining the board and Novartis/Kite as observers. In October 2020, Vineti closed a $33 million extension to its Series C, again led by Cardinal Health, with Marc Benioff, Canaan Partners, Threshold Ventures, Section 32, Casdin Capital, Novartis Pharma AG, McKesson Ventures, and LifeForce Capital participating; Eli Casdin joined the board. One source notes a total of approximately $68.4 million raised by November 2020 across tranches, aiming for $75 million. The extension funded expansion of the Personalized Therapy Management (PTM) platform. Vineti was involved in hundreds of global projects, supporting clinicians and patients in hundreds of leading medical centers worldwide in 2020. It addresses challenges in delivering personalized medicine, amid growing cell and gene therapy trials (over 1,050 worldwide, potentially enrolling 60,000 patients). |
| Feb 2020 | Series C | Cardinal Health (lead); Gilead Sciences; Canaan Partners; Casdin Capital; dRx Capital; Kite Pharma; Novartis; S32; Lifeforce Capital; Threshold; Hive Ventures | $35M | - | Vineti is a US-based company providing a cloud-based digital platform for personalized therapy management (PTM), integrating logistics, manufacturing, and clinical data to manage complex supply chains for cell and gene therapies, CAR-T, and other advanced therapeutics. Co-founded by General Electric and Mayo Clinic, the platform ensures chain of identity and custody, supports clinical and commercial stages, and aids biopharma, providers, and regulators in delivering therapies globally. In February 2020, Vineti completed a $35 million Series C financing round led by Cardinal Health, with participation from Novartis Pharma AG, Kite (a Gilead company), Canaan Partners, Threshold Ventures, Section 32, LifeForce Capital, Casdin Capital, Hive Ventures, and others. The funds were allocated to enhance automation and analytics, develop new software products, expand commercially in Europe and Asia-Pacific, and industrialize personalized medicine. Cardinal Health's Joe DePinto joined the board, with Novartis and Kite as observers. This brought total funding over $82 million, following a $33.5 million Series B and $13.8 million Series A. Later in 2020, Vineti extended its Series C with additional tranches, including a $33 million extension in October led by Cardinal Health with Marc Benioff, McKesson Ventures, and existing investors like Casdin Capital (Eli Casdin joined the board), reaching approximately $68.4 million total by November. The platform supported clinicians and patients in hundreds of leading medical centers worldwide in 2020 and was involved in hundreds of global projects, including autologous and allogeneic programs amid growing cell/gene therapy trials. The market context includes rapid growth in advanced therapies, with expectations of 10-20 approvals yearly by 2025 and over 1,050 clinical trials enrolling nearly 60,000 patients. |
| Apr 2018 | Series B | Canaan Partners (lead); Threshold (lead); Casdin Capital; Mayo Clinic Ventures; S32; GE Ventures; Lifeforce Capital | $34M | - | Vineti, Inc. is a San Francisco-based software automation and analytics platform designed specifically for cell and gene therapies. Its configurable, cloud-based platform improves product performance, ensures regulatory compliance, and facilitates faster, safer patient access by automating complex workflows, providing chain of custody and identity tracking, and integrating with the broader therapy ecosystem. The company supports pharmaceutical partners including Kite (Gilead), helping with FDA approvals like Yescarta, and serves a growing global network of patients, providers, and researchers. On April 16, 2018, Vineti raised $33.5 million in Series B funding led by Canaan Partners and Threshold (then DFJ), with participation from GE Ventures, Section 32, Casdin Capital, LifeForce Capital, and others. The funds were earmarked to advance its cloud-based 'platform of record' for personalized therapies like CAR-T, and to expand operations in Europe and Asia-Pacific amid the field's rapid growth following 2017 FDA approvals of Novartis and Kite therapies. Vineti had previously secured funding, with total raised reaching about $47.3M by April 2018 across rounds. Later, in a Series C (date unspecified, ~2021), it raised $35M led by Cardinal Health with Novartis and Kite, plus existing investors. The 2018 timing aligns with surging interest in cell/gene therapy infrastructure post-commercial launches. |
| Jun 2017 | Series A | GE Ventures (lead); Mayo Clinic Ventures; Lifeforce Capital; Threshold | $14M | $28M | Vineti is a cloud-based software platform for cell and gene therapy manufacturing and delivery, co-founded by GE Ventures and Mayo Clinic Ventures. The platform automates complex workflows in personalized medicine such as CAR-T immunotherapies, integrating logistics, manufacturing, and clinical data to improve product performance, regulatory compliance, and patient access. In June 2017, Vineti closed its Series A financing round at a post-money valuation of $28.18 million, raising $13.75 million from GE Ventures, Mayo Clinic Ventures, DFJ, and LifeForce Capital. The company was founded by industry veterans including CEO Amy DuRoss, CSO Heidi Hagen, CTO Razmik Abnous, and Chief Science Officer Malek Faham, who had been working directly with customers to develop the platform. By the time of the Series A close, Vineti had secured its first major commercial partnership with Kite Pharma to support their CAR-T therapy delivery. |
Who has invested in Vineti?
15 investors have backed Vineti across its funding rounds, including Threshold, Lifeforce Capital, Canaan Partners, Casdin Capital, S32 and GE Ventures.
Lead investors include Cardinal Health, Canaan Partners, Threshold and GE Ventures.
Vineti Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| San Francisco, CA | 4 | Participant | Jun 2017 | |
| San Francisco, CA | 4 | Lead | Jun 2017 | |
| United States | 3 | Lead | Apr 2018 | |
| New York City, NY | 3 | Participant | Apr 2018 | |
| San Diego, CA | 3 | Participant | Apr 2018 | |
| United States | 2 | Lead | Feb 2020 | |
| United States | 2 | Participant | Jun 2017 | |
 Basel | 2 | Participant | Feb 2020 | |
| Menlo Park | 2 | Lead | Jun 2017 | |
| San Francisco, CA | 1 | Participant | Feb 2020 | |
| San Francisco, CA | 1 | Participant | Oct 2020 | |
| Basel | 1 | Participant | Feb 2020 | |
| Los Angeles, CA | 1 | Participant | Feb 2020 | |
This data is available for Pro users. Sign up to see all 15 Vineti investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialVineti Competitors
Vineti competitors include listed companies like Nano X Imaging and Aclarion, and private ones like VideaHealth, Condor Software, Pivotal Analytics and Taxo.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Boston, MA | Private | - | - | $28M | - | |
| San Diego, CA | Private | - | - | $29M | - | |
| Pittsburgh, PA | Private | - | - | $27M | - | |
| San Francisco, CA | Private | $1M | - | $30M | 30.0x | |
| United States | Publicly listed | $13M | ($67M) | $62M | 2.1x | |
| United States | Publicly listed | $76K | ($7M) | $8M | - |
Vineti Public Comps
Vineti is still privately-owned, but its public comps include Carelabs, Shelfie-Tech, Healixa, CID Holdco, 111, NextPlat, Doctor Care Anywhere, iTonic Holdings, Metacare and CareView Communications.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $59M | $19M | 0.1x | - | 0.5x | - | |||
| - | ($691K) | - | - | (38.7x) | - | |||
| - | - | - | - | - | - | |||
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} CID Holdco | $6M | ($36M) | 4.6x | - | (0.7x) | - | ||
| $1.9B | $3M | 0.0x | 0.0x | 15.8x | - | |||
| $54M | ($10M) | 0.3x | 0.3x | (1.5x) | - | |||
| $51M | $6M | 0.6x | 0.6x | 5.5x | 4.5x | |||
| $523K | ($5M) | 63.4x | - | (6.5x) | - | |||
This data is available for Pro users. Sign up to see all Vineti competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Vineti
| When was Vineti founded? | Vineti was founded in 2016. |
| Where is Vineti headquartered? | Vineti is headquartered in San Francisco, CA, United States. |
| Is Vineti publicly listed? | No, Vineti is a private, VC-backed company. |
| What is Vineti's valuation? | Vineti was last valued at $28M in its Series A in June 2017. |
| How much funding has Vineti raised? | Vineti has raised $115M across 4 funding rounds. |
| What was Vineti's last funding round? | Vineti's last funding round was a $33M Series C in October 2020, led by Cardinal Health. |
| Who are Vineti's investors? | Vineti's investors include Lifeforce Capital, Threshold, Canaan Partners, Casdin Capital, S32, Cardinal Health, Mayo Clinic Ventures, Novartis, GE Ventures, Gilead Sciences and 5 others. |
| Which companies are comparable to Vineti? | Companies comparable to Vineti include VideaHealth, Condor Software, Pivotal Analytics, Taxo, Nano X Imaging and Aclarion. |
See companies similar to Vineti
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.